Abstract
Objectives: This work is aimed to summarize the first year of the high-risk human papillomavirus (hrHPV) screening test and compare it to the cytology screening test, regarding positivity rates and premalignant lesions diagnosed in the Israeli population. A specific consideration is for the age group 25–30 that is not considered mandatory for the HPV primary screening testing. Methods: A retrospective study was performed in women who were screened for prevention of cervical cancer in Maccabi HealthCare HMO from March 2017 to March 2019. Screening methods included hrHPV typing for types 16, 18, and the other 12 hrHPV types and the PAP LBC test. Results: A total of 115,807 cervical samples were tested for HPV presence and 91% (105,225) were found negative for hrHPV. The other 9% (10,582) were positive for one or more of the 14 hrHPV types tested, and 37% (3,916) of them showed abnormal PAP LBC results. In the age group of 25–30, 3,104 (17.5%) women were found positive for hr-HPV (825 had hrHPV types 16 and/or 18), of which 42% (1,293) of them showed abnormal PAP LBC results. During the hrHPV versus PAP LBC screening era, 258 more women were diagnosed with precancerous cervical lesions (CIN2/3), 70% increased detection versus cytology screening. Conclusions: The hrHPV screening test is currently the best method for the detection of precancerous cervical lesions and cervical cancer, and it is better started at age 25.
References
1.
Sawaya
GF
, McConnell
KJ
, Kulasingam
SL
, Lawson
HW
, Kerlikowske
K
, Melnikow
J
, Risk of cervical cancer associated with extending the interval between cervical-cancer screenings
. N Engl J Med
. 2003
;349
(16
):1501
.2.
Schoolland
M
, Allpress
S
, Sterrett
GF
. Adenocarcinoma of the cervix: sensitivity of diagnosis by cervical smear and cytologic patterns and pitfalls in 24 cases
. Cancer
. 2002
;96
(1
):5
–13
.3.
Tabrizi
SN
, Brotherton
JM
, Kaldor
JM
, Skinner
SR
, Cummins
E
, Liu
B
, Fall in human papillomavirus prevalence following a national vaccination program
. J Infect Dis
. 2012
;206
(11
):1645
–51
. .4.
Wright
TC
, Bosch
FX
, Franco
EL
, Cuzick
J
, Schiller
JT
, Garnett
GP
, Chapter 30: HPV vaccines and screening in the prevention of cervical cancer;conclusions from a 2006 workshop of international experts
. Vaccine
. 2006
;24
(Suppl 3
):S3/251
.5.
Ronco
G
, Dillner
J
, Elfström
KM
, Tunesi
S
, Snijders
PJ
, Arbyn
M
, Efficacy of HPV-based screening for prevention ofinvasive cervical cancer: follow-up of four European randomised controlled trials
. Lancet
. 2014
;383
(9916
):524
–32
.6.
Dillner
J
, Rebolj
M
, Birembaut
P
, Petry
KU
, Szarewski
A
, Munk
C
, Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study
. BMJ
. 2008
;337
:a1754
.7.
Cuzick
J
. Role of HPV testing in clinical practice
. Virus Res
. 2002 Nov
;89
(2
):263
–9
.8.
Menczer
J
, Kogan
L
, Schejter
E
, Liphshiz
I
, Barchana
M
. A population-based study of selected demographic characteristics of Israeli-Jewish women with cervical squamous cell carcinoma
. Arch Gynecol Obstet
. 2011
;283
(3
):629
–33
. .9.
Schejter
E
, Tsamir
J
, Fridman
N
. Compliance with opportunistic pap screening in Israel
. Bull Isr Soc Obs Gynecol
. 2003
;2
:67
–70
.10.
Huh
WK
, Ault
KA
, Chelmow
D
, Davey
DD
, Goulart
RA
, Garcia
FA
, Use of primary high-risk human papillomavirus testing for cervical cancer screening: Interim clinical guidance
. J Low Genit Tract Dis
. 2015
;19
(2
):91
–6
. .11.
Elfström
KM
, Arnheim-Dahlström
L
, von Karsa
L
, Dillner
J
. Cervical cancer screening in Europe: quality assurance and organisation of programmes
. Eur J Cancer
. 2015
;51
(8
):950
–68
. .12.
Clifford
GM
, Gallus
S
, Herrero
R
, Muñoz
N
, Snijders
PJ
, Vaccarella
S
, Worldwide distribution of human papillomavirus types in cytologically normal women in the International agency for research on cancer HPV prevalence surveys: a pooled analysis
. Lancet
. 2005
;366
(9490
):991
–8
. .13.
Sadan
O
, Schejter
E
, Ginath
S
, Bachar
R
, Boaz
M
, Menczer
J
, Premalignant lesions of the uterine cervix in a large cohort of Israeli Jewish women
. Arch Gynecol Obstet
. 2000
;269
:188
–91
. .14.
Arbel-Alon
S
, Menczer
J
, Feldman
N
, Glezerman
M
, Yeremin
L
, Friedman
E
. Codon 72 polymorphism of p53 in Israeli Jewish cervical cancer patients and healthy women
. Int J Gynecol Cancer
. 2002
;12
(6
):741
. .15.
Quddus
MR
, Manna
P
, Sung
CJ
, Kerley
S
, Steinhoff
MM
, Lawrence
WD
. Prevalence, distribution, and viral burden of all 15 high-risk human papillomavirus types in adenosquamous carcinoma of the uterine cervix: a multiplex real-time polymerase chain reaction–based study
. Hum Pathol
. 2014
;45
(2
):303
–9
.16.
Ronco
G
, Giorgi-Rossi
P
, Carozzi
F
, Confortini
M
, Dalla Palma
P
, Del Mistro
A
, Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial
. Lancet Oncol
. 2010
;11
(3
):249
.17.
Ogilvie
GS
, van Niekerk
D
, Krajden
M
, Smith
LW
, Cook
D
, Gondara
L
, Effect of screening with primary cervical HPV testing vs cytology testing on high-grade cervical intraepithelial neoplasia at 48 months: the HPV FOCAL randomized clinical trial
. JAMA
. 2018 Jul
;320
(1
):43
–52
.18.
Liverani
CA
, Di Giuseppe
J
, Giannella
L
, Delli Carpini
G
, Ciavattini
A
. Cervical cancer screening guidelines in the postvaccination era: review of the literature
. J Oncol
. 2020
.19.
Fontham
ETH
, Wolf
AMD
, Church
TR
, Etzioni
R
, Flowers
CR
, Herzig
A
, Cervical cancer screening for individuals at average risk: 2020 guideline update from the American Cancer Society
. CA Cancer J Clin
. 2020 Sep
;70
(5
):321
–46
. .20.
Von Karsa
L
, Arbyn
M
, De Vuyst
H
, Dillner
L
, Dillner
J
, Franceschi
S
, Executive summary
. In: Anttila
A
, Arbyn
A
, De Vuyst
H
, Dillner
L
, Dillner
J
, Franceschi
S
, editors. European guidelines for quality assurance in cervical cancer screening
. 2nd ed. Luxembourg
: Office for Official Publications of the European Union
; 2015
.© 2021 S. Karger AG, Basel
2021
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
